IQVIA (IQV)
(Delayed Data from NYSE)
$240.84 USD
+2.22 (0.93%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $240.72 -0.12 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
IQV 240.84 +2.22(0.93%)
Will IQV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IQV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IQV
Reasons to Retain IQVIA (IQV) Stock in Your Portfolio Now
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
IQV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
IQVIA (IQV) Appreciates 24% in a Year: Here's What to Know
Other News for IQV
IQVIA Holdings Inc (IQV)'s Winning Formula: Financial Metrics and Competitive Strengths
Medpace raised to Buy at Jefferies after Q1 earnings beat
IQVIA Celebrates Wendy Stewart and Susan Barnes, Winners of Healthcare Businesswoman's Association Luminary and Rising Star Awards
Strategies for Biomarker-Driven Sub-population Optimization in Clinical Trials, Upcoming Webinar Hosted by Xtalks
Bank of America Securities Reaffirms Their Buy Rating on IQVIA Holdings (IQV)